Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Decreases Neurofilament Light Chain Levels Over 2.5 Years of Treatment in Patients with Relapsing Multiple Sclerosis

Authors
Category Primary study
JournalMultiple sclerosis and related disorders
Year 2023
This article has no abstract
Epistemonikos ID: 283409152aaaa74a862c2621c7006b08471938c9
First added on: Feb 16, 2024